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Abstract 
 
The regulation and registration of traditional medicines (TM) continues to present challenges to many countries 
regardless of the fact that an increased number of the population utilises TM for their health care needs.  There have been 
improvements in the legal and policy framework of South Africa based on the WHO guidelines.  However, there are currently no 
guidelines or framework for the registration of TM in South Africa.  This article reviews literature and existing guidelines of 
specific countries and regions and makes recommendations for South African guidelines.   
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Introduction 
 
Traditional medicines (TM) and plant-based remedies are widely used in Africa. It has been estimated that 80% of the 
African population relies on traditional forms of medicine to meet their healthcare needs (World Health Organisation (WHO), 
2004). Worldwide the trend has also shifted towards the use of TM due to concerns about the costs, invasiveness and potential for 
toxicity of conventional mainstream remedies (Cowan, 1999). Most of these TM are not well-researched, poorly regulated, may 
contain adulterated products, and may produce adverse effects (Mills et al., 2005). Traditional medicines are defined as the sum 
total of knowledge, skills and practices based on the theories, beliefs and experiences indigenous to different cultures, whether 
explicable or not, used in the maintenance of health as well as in prevention, diagnosis, improvement or treatment of physical or 
mental illnesses (WHO, 2001). Over the last fifteen years the safety and efficacy of TM, as well as quality control, have become 
important concerns for both health authorities and the public (WHO, 2005). 
It is important to identify that various practices exist in different cultures of the world, and therefore it would be difficult 
to develop uniform regulations for registration of TM. A 2005 survey of the WHO on national policy on traditional medicine and 
regulation of herbal medicines in member countries identified a lot of challenges in the development of such regulations. These 
range from regulatory status, safety and efficacy assessment, quality control and standardisation, safety monitoring and lack of 
knowledge about traditional, complementary and alternative medicines (TCAM) by relevant national drug regulatory authorities 
(WHO, 2005). Implementation of such regulatory matters in developing countries where TM still form the backbone of the 
healthcare systems is also hampered by lack of resources.  
The TM law of each country should include and define the regulatory status, claim types, pharmacopoeia and 
monographs used, manufacturing requirements and control mechanisms, safety requirements, registration systems, etc. Basically 
the regulations are drafted to implement the National Policy on TM (WHO, 2005). South Africa has taken various initiatives to 
promote the regulation of TM and its practices. The national drug policy which includes TCAM was developed in 1996. The 
Policy recognizes the potential role of and benefits of available remedies of TM in the National Health System. It is aimed at 
investigating the use of effective and safe TM at primary level. It further stipulates; (1) the investigation of TM for efficacy, safety 
and quality with the aim to incorporate their use in the national health care delivery system and, (2) registration and control of 
marketed TM. Other initiatives include the establishment of two expert committees on African TM and CAM, to advise the 
Medicines Control Council (MCC) (Gqaleni et al., 2007).  
Unfortunately the regulatory framework for registration of TM specifically designed to provide the legal machinery to 
achieve the administrative and technical goals of the National Policy is still under development.  The national pharmacopoeia and 
monographs on herbal medicines are also still in development. Manufacturing and safety assessment requirements are similar to 
good manufacturing practice (GMP) rules as those used by conventional pharmaceuticals. According to the WHO survey on 
regulation of TM and, specifically, herbal medicines showed that 65% of Member States have laws or regulations on herbal 
medicines and these regulations are largely similar to those of conventional medicines. Out of these, 61% reported that they have 
registration systems for herbal medicines (WHO, 2005). South Africa, as a country still developing its regulations, can learn a lot 
from these countries with regulations and registration systems for herbal medicines.  
In developing regulations for registration of herbal medicines in South Africa, it is important to take into consideration 
the uniqueness of the TM systems in this country and then compare it with those countries with developed regulations. The 
guidelines to be developed by the MCC expert committee must also be guided by the WHO guidelines for registration of 
traditional and complementary medicines in the African region, which South Africa adopted as a member state (WHO, 2004). 
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Table 1: A summary of regulatory guidelines for registration of traditional medicines (TM) in different countries and regions of the world (FDA, 2006; EMEA,20061, 2;  Deal,2010;  
Australian government, 20051, 2; WHO,2004).   
Requirements for 
registration of TM 
Food and DrugAdministration 
(United States of America) 
European Medicines Agency 
(European Union) 
Australian Guidelines for 
Complementary Medicines 
WHO Guidelines for registration of 
TM in African region 
Traditional use Not considered Traditional use does not substitute 
quality. Bibliographical evidence of 
traditional use must be presented 
Use of TM must be well established and 
widely acknowledge; effective preparation, 
dosage, method of use and indications are 
well established; botanical identification of 
herbal substance(s) 
Traditional use not addressed directly but 
it is considered in evaluation of safety & 
efficacy of TM  
Pharmaceutical 
Quality 
As conventional drugs Starting materials must be defined 
by botanical identification and 
quality must adhered to until the 
final herbal product 
Each ingredient in formulation should be 
characterized; state the plant part used and 
processing before use in manufacture of the 
product; brief description of manufacturing 
process must be provided 
Raw plant material(s) should identified; 
state plant part used; chemical, physical 
& biological tests for general 
identification; finished product 
qualitatively & quantitatively analysed   
Stability Testing As conventional drugs Stability should be determined by 
appropriate fingerprint 
chromatograms  
Stability data must be sufficient to 
demonstrate that the product intended for 
market will remain safe, of consistent 
quality and efficacious throughout its shelf 
life. Maximum permitted shelf life is 5 
years 
Stability tests fall under quality 
evaluation of raw & finished product 
Safety As conventional drugs Bibliographical evidence of safety 
including cross-referencing to 
Expert report. Safety summary 
including herbal ingredients, use in 
pregnancy & lactation and possible 
drug interactions must be included  
Traditional use not a substitute for safety. 
Long-term and safe therapeutic use will be 
considered in evaluating the safety of 
products. Safety summary including herbal 
ingredients, use in pregnancy & lactation 
and possible drug interactions must be 
included 
Botanical authentication of raw plant(s); 
biological information obtained via 
literature/database search; standard 
toxicological studies mandatory even of 
long-term use history is available  
Therapeutic 
Efficacy 
As conventional drugs Efficacy must be plausible on the 
long-standing use and experience 
Traditional use will be taken into account 
when establishing efficacy. Where 
traditional use is not sufficient, clinical 
evidence data should be provided.  
Efficacy dependent on kind of indications 
for use & individual experiences of 
doctors, THPs or patients. Clinical 
evidence is required traditionally-use 
plants for a new indication. Active 
ingredients should be standardised if 
known; if actives are not, whole TM 
should be taken active ingredient.  
Labeling and 
packaging  
As conventional drugs Packaging leaflet shall reflect the 
results of consultations with target 
patient groups to ensure that it is 
legible, clear and easy to use 
Labels should reflect all the necessary 
information about the product as guided by 
the Australian Therapeutics Goods Act 
1989  
Labeling & packaging is addressed under 
quality control and good manufacturing 
practices of the finished product 
Multi-ingredient 
products  
Each product must clearly 
identified tested separately 
Quantitative determination of each 
active substance separately 
Traditional formulations will normally be 
accepted unless current adverse evidence 
exists. New formulations should provide 
information of efficacy of each herbal 
ingredient 
Multi-ingredient products not mentioned 
directly but the guidelines do mention 
formulations of herbal medicines in 
quality, safety and efficacy assessment 
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REGULATION AND REGISTRATION SYSTEMS FOR TRADITIONAL MEDICINES OF SPECIFIC COUNTRIES 
AND REGIONS    
 
Regulations for TCAM in each country serve as a framework for implementation of National Policies and propose a 
method for registration of TM. The framework of the regulations is intended to simplify and accelerate the registration and 
standardization of TM and they set out criteria such as pharmaceutical quality, stability testing, safety, therapeutic efficacy, 
labeling and packaging, multi-ingredients TM, and traditional use. Quality of TM relates to the formulation of the medicines and 
ensuring consistent quality from batch to batch. Safety specifies that the TM should have higher benefits than risk while efficacy 
means that the TM should be effective for the indications claimed and should clinically significant and useful. The guidelines are 
aimed at national drug regulatory authorities, traditional health practitioners (THPs) and institutions involved in TM research and 
development of related products (WHO, 2004 & WHO, 2005).   
The WHO guidelines for registration of TM in the African region have also classified TM into different categories according to 
how they are prepared. Category 1 TM, are those prepared by THPs for treatment of individual patients and these are normally not 
regulated by laws of the country but by THPs themselves. Traditional medicines which are widely used in the community, their 
formulation is known and possible commercial value fall under category 2 TM. The third category caters for TM which have been 
developed through scientific research. Category 4 TM are imported TM and should meet the requirements for the regulation of 
TM of the country into which they are being imported into (WHO, 2004). The guidelines for registration of TM in Southeast Asia 
region under the WHO have a similar structure to those of the African region and this highlights the long history of TM use in 
both regions (WHO, 2003) (Table 1). 
A summary of the requirements for registration of TM in Australia, United States of America (USA), European Union 
and the WHO African region is presented in Table 1.   According to Table 1, the Food and Drug Administration (FDA) of the 
USA has developed its own draft guidelines for regulation of complementary and alternative medicines (CAM). It has devised 
four “domains” to classify CAM and TM might fall into 1 or 2 of these domains; either biologically-based practices or whole 
medical systems. Botanical products fall under biologically-based products which will include the traditional herbal medicines. 
Any new herbal product identified as treating a specific disease is treated as any new conventional drug and will have to meet 
similar safety and efficacy requirements (FDA, 2006). The European Medicines Agency (EMEA) has similar registration 
requirements but also state that the quality of a medicinal product is independent of its traditional use and therefore all general 
principles of quality apply to traditional herbal medicines for human use (EMEA, 2006a, b; Deal, 2010).  
The Australian regulatory guidelines have references to traditional use of herbs or herbal mixtures and to multi-
ingredient products. It states that traditional use is not a substitute for safety but will be considered in the evaluation of efficacy of 
the herbal medicine. Traditional multi-ingredient products are normally accepted unless current adverse evidence exists. New 
formulations are assessed as any other new drug (Australian government, 2005a).  The WHO guidelines for registration of TM in 
the African region provide Member States with the framework for development of regulations. Theses guidelines provide the 
minimum requirements for registration of TM regarding pharmaceutical quality, safety, stability testing, therapeutic efficacy, and 
labeling and packaging. Because of the diversity of TM types product in Africa, the WHO guidelines has created four (4) 
categorises TM to simplify the implementation of mechanisms of registration. These categories range from THP remedies 
prepared for individual patients to TM derived from scientific research (WHO, 2004). Therefore South Africa, as a Member Sate 
of the WHO, has the necessary framework to develop regulations for registration of TM. 
The regulations and guidelines for registration of TM are aimed at all stakeholders, including national drug regulatory 
authorities; in case of South Africa the Medicines Control Council), Traditional Health Practitioners (THPs), manufacturers and 
drug research institutions. Traditional health practitioners (THPs) and the TM system of the country therefore need to be 
developed along with the development and implementation of regulations for registration of TM. This can be achieved by 
regulating the THP practices and having all THPs registered. This will allow THPs to be part of the processes of development of 
regulations that will control their medicinal products. This will serve as a great educational tool for the THPs involved in this 
process and they can in turn deployed to educate other healers. The use of pharmacopoeias and monographs for naming of 
traditional medicine products will require good understanding from THPs who will want to have their products registered. The 
idea of involving THPs in all these processes is simply because they are the knowledge holders and their involvement will help to 
safeguard their intellectual property (IP). 
 
CONSIDERATIONS FOR THE DEVELOPMENT OF GUIDELINES FOR REGISTRATION OF TRADITIONAL 
MEDICINES IN SOUTH AFRICA 
 
It is estimated that about 70-80% of the South African population consults one of the over 200 000 THPs for their 
primary healthcare needs. It is for this reason that there has been recognition of traditional medicine practices in South Africa 
(Gqaleni et al., 2007; WHO, 2005). It is therefore very regrettable that the TM system is still not yet regulated by law. Some 
progress has been made by the National Department of Health to provide for a regulatory framework to register, regulate and 
control THP (THP Act No. 22, 2007). The THP Act will establish an Interim THP Council. The Council will oversee the 
registration and regulation of the practice of traditional healers by setting practice standards. The establishment of the African 
Traditional Medicines Expert Committee to advise the MCC is also expected to expedite the process towards development of 
regulations.  
The guidelines being developed in South Africa should also consider the type of TM to be registered. The WHO 
guidelines for the African region classify TM products into four different categories according to how they are prepared. Category 
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1 TM are those remedies prepared by THPs for specific patients during consultations and are not to be regulated (WHO, 2004). 
The same regulation should be applied in the South African guidelines because such remedies prepared for individual patients 
change according the presentation of that patient to the healers. Only traditional herbal medicines prepared for commercial sale 
should be registered and these must follow the registration guidelines of safety, efficacy and pharmaceutical quality. As specified 
by the EMEA (2006a) and Australian government (2005a), traditional use of the remedy or formulation should be taken into 
consideration when evaluating safety and efficacy but these should not replace scientific evaluation of claims.            
Most TM which claim to provide “effective cures” for various ailments lack scientific evidence of safety, efficacy or 
pharmaceutical quality. Generally speaking, researchers in the WHO African region lack the facilities for the assessment of 
quality, safety and efficacy of TM. This is partly because of the complex composition of many TM. South Africa is privileged in 
that in has the researchers and some facilities to assess the TM products. The National Reference Centre for African Traditional 
Medicines is an initiative spearheaded by the Department of Health, in partnership with the Council for Scientific and Industrial 
Research and the Medical Research Council. The centre's remit is to gather, harness and synthesise information to promote, 
regulate and register African TM of plant origin (Pefile, 2005). Other science councils and universities are also involved in 
various areas of TM research.  
 
RECOMMENDED STRUCTURE OF THE SOUTH AFRICAN GUIDELINES FOR REGISTRATION OF 
TRADITIONAL MEDICINES 
 
The main purpose of implementing the regulation and registration of TM is to protect the consumers of these medicines. 
But in enforcing these regulations, the authorities must that many pharmaceutical medicines are derived from plants based on the 
power active compounds they contain (Deal, 2010). Traditional medicines have also been used for centuries in Africa and their 
regulation is a reversal of the regulatory process for pharmaceutical drugs in that they are already being consumed. In building 
from the minimum requirements for registration of TM set out by the WHO African region, the South African regulations must 
take into account the reality of TM being widely used already and the resources available in the country. The more stringent 
regulatory guidelines of developed countries are mostly aimed at herbal companies while in Africa it is mostly THPs who will 
have to comply with these regulations. It is these factors and the reality that just because the remedy is a herbal medicine does not 
mean that the consumer will not suffer side-effects.  
 It is important to also consider possible interactions between TM and other medicines (Deal, 2010). We have therefore 
reflected on the regulatory requirements of the FDA, EMA, Australian government and the WHO to come with some 
recommendations in the development of guidelines for registration of TM in South Africa. These recommendations are meant to 
minimise the registration requirements while having the best possible impact in protecting the consumer. Our recommendations 
apply only to traditional herbal medicines as defined by the WHO.  
 
Traditional use 
 
African TM systems have been in existence for many centuries and conceptual framework is different from that of 
modern medicine. Traditional use will therefore be used to define herbal medicines which are intended and used without the 
intervention of medical practitioner for diagnosis, prescription or monitoring of treatment. The use of such medicines must be 
well established between many THPs over a long time and widely acknowledged. The efficacy must be credible on the basis of 
long-term use and experience. The botanical identity of the plant must be known and proven through bibliographical evidence. 
Such evidence can be sourced from handbooks of medicine, pharmacology, pharmacopeias, etc (Deal, 2010; Australian 
government, 2005a).   
 
Pharmaceutical quality 
 
Ensuring quality of TM products is a shared responsibility of the MCC and the manufacturers of the products. 
Requirements for quality control are well covered in the WHO guidelines for registration of TM in the African region (2005). 
Additional requirements that should be added include ensuring that the raw materials and finished products contain the same 
amount of active ingredients. Adherence to Good Agricultural and Collection Practice (GACP), Good Laboratory Practice (GLP) 
and (GMP) must be enforced to ensure pharmacovigilance in collection of raw materials and manufacturing of the finished 
products. Generally the herbal products must contain the correct ingredients of acceptable ingredients, uncontaminated, and the 
stated shelf life of the product must be supported by documented evidence. Specifications for the raw and finished products 
should be provided, identifying physical, chemical and microbiological characteristics of the product and detailing quality control 
test methods. If the product is a multi-ingredient product, each herbal ingredient in the formulation should be characterized 
(EMEA, 2006a; Deal, 2010; Australian government, 2005a).       
 
Stability testing 
 
Stability data produced by the applicant must demonstrate that the product intended for the market will remain safe, of  
consistent quality and have efficacy throughout its stated shelf life. Since most TM products in their entirety are regarded as active 
ingredients, the stability of all substances that form part of the final product. This should be determined by appropriate 
chromatographic fingerprinting and other specific sensory and physical tests. Known active constituents of the product should not 
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show a significant variation during the sated shelf life. Products with unknown therapeutic actives which have not been 
quantified, the stated shelf life should be justified by appropriate chromatographic profiling. Physical characteristics such as 
colour or odour changes, and precipitation should be also included (EMEA, 2006a; Australian government, 2005a).   
 
 
 
Safety 
 
Traditional use of TM should not be a substitute for safety but must be taken into consideration when safety is 
evaluated. Where traditional use is used as safety evidence, the details of use (duration, route, dose etc.) should be consistent with 
the proposed use. Safety is dependent upon the formulation of the product overall, its intended therapeutic purpose, dosage, route 
of administration, duration of use, the patient group (such as children, the elderly, and pregnant and lactating women) and possible 
interactions with critical medication. Where the data documenting a tradition of use is insufficient, or there are suspicions of 
effects that are difficult or impossible to detect with population or clinical studies, the safety evaluation will need to be supported 
with other studies (e.g. by in vitro and in vivo single and repeat-dose toxicity, immunotoxicity, reproduction (embryo/fetal, 
prenatal toxicity), mutagenicity/genotoxicity and carcinogenicity studies) (Deal, 2010; WHO, 2003; Australian government, 
2005a). 
  
Therapeutic efficacy 
 
Long-term use of TM will have to be considered when efficacy is evaluated. Bibliographical evidence from herbal 
books, pharmacopeias, peer-reviewed scientific papers etc., must be presented along with the application to prove traditional use. 
When the TM product is used for non-traditional purposes, new evidence must be presented to support the therapeutic use. This 
evidence can be made up of in vitro and in vivo animal models as a minimum requirement. The type of evidence presented will 
depend on the kind of indications for use and individual experiences as recorded in reports from physicians, THPs or treated 
patients (Australian government, 2005a).  
New evidence might be required for new formulations of TM. This new evidence should address issues related to 
pharmacodynamics, pharmacokinetics, bioavailability and possible clinical trials. We recommended that it would be more feasible 
for THPs to have their TM products evaluated by in vitro and in vivo animal models for their pharmacodynamics, 
pharmacokinetics, and bioavailability effects. Pharmacodynamics details the possible mechanism of action, dose and dose 
intervals, and possible drug interactions. Pharmacokinetics describes what happens inside the body once the medicine is taken by 
the patient and includes the absorptions, distribution, metabolism and elimination. Bioavailability describes the proportion of 
administered medicine reaching systemic circulation. This is affected by the route of administration of the medicine with 
intravenous injection taken as 100% bioavailability (Australian government, 2005b). Clinical trials of TM, although desirable, 
might not be a feasible requirement for registration of TM from THPs.       
 
Multi-ingredient TM products 
 
The reality of African TM products is that most of them are made up of different herbs mixed to form one product. 
Some of the multi-herbal products are based on centuries of knowledge and it is assumed that the ingredients contribute and 
undefined range and balance of pharmacologically active compounds to their overall therapeutic use. These traditional 
formulations can be registered based on long-term use unless current adverse evidence exists. New multi-herbal product should 
have each plant tested separately for quality, safety, efficacy and stability (Australian government, 2005a).  
 
Labeling and packaging 
 
The WHO guidelines for the African region have very clear requirements for labelling of TM. These cover quantitative 
listing of active ingredients, identifying the plant names, dosage form, therapeutic indications, manufacturing and expiry date, lot 
number and the name of the manufacturer (WHO, 2005). Requirements that can be added to these include ensuring that the labels 
reflect the results of consultations with target patient group groups to ensure that it is legible, clear and easy to use. The aim of 
this is to demonstrate that patients can understand and know how to act on the instructions of the labeling (Deal, 2010). Packaging 
should form part of the GMP requirements for manufacturers of TM products. Detailed specifications of the type, nature, size and 
grade of the primary container should be given including the method of closure and, for liquid products, fill volume (Australian 
government, 2005b).       
 
Post-approval market monitoring     
 
National surveillance systems at different levels on the health sector should be put in place in order to monitor and 
evaluate any reported adverse effects of traditional medicine. This can be done by enhancing the existing national safety 
monitoring and pharmacovigilance systems to include Traditional Medicine (TM). The objective of the surveillance system will 
be to provide assurance and consumer confidence in the safety and quality of TM. It will also ensure industry compliance with 
regulator standards and guidelines for TM. Measures that are to be required to meet the regulations include targeted and 
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randomised audits of registered TM, monitoring of suspected adverse events, randomised laboratory testing of TM, monitoring of 
the market place and an effective, responsive and timely recall procedure. The regulatory authority should also control advertising 
by approving every advertising campaign of registered TM products (Australian government, 2005a).      
 
PROPOSED ANALYSES TO BE UNDERTAKEN TO ENSURE THE TRADITIONAL MEDICINES MEET BASIC 
REQUIREMENTS 
 
The requirements for registration of South African TM should not be beyond the means which could be met by THPs. 
At the same these requirements should be drafted in such a way that they protect the consumers of TM. Therefore a fine balance 
must be struck between preserving traditional healing knowledge and meeting the highest standard of health services. It must be 
said the even the minimum requirements set by WHO for the Africa region are hard to meet for an ordinary THP. Therefore 
government will have to play an important role in sponsoring the development of TM and traditional healing as a whole. This 
support will go beyond developing this sector but will need to also to support institutions which will set quality control standards 
for these requirements. Below we have outlined what we thinking are important minimum requirements that need to be met by 
TM products in order for them to be registered as medicinal products.   
 
Microorganisms and heavy metal screening- quality control of raw plant material  
 
Plant materials are naturally exposed to microorganisms and heavy metals which can be found in the environment. The 
introduction of microbial population in TM (TM) can be either in raw form or finished product; and all of this, depends on the 
matter in which the plant material is being sampled and prepared and packed. Heavy metal can be indirectly introduced into plant 
material via natural process or directly as to improve or enhance that particular TM.     
Microorganisms are widely distributed in the environment. Traditional medicine(TM) can be contaminated by 
microorganisms that can be traced back to the bush where samples are being collected, and also during the preparation of plant 
materials into medicinal plants and storage and packages.  Microorganisms have been reported to degrade the quality of some 
bioactive such as sterols and sterolins which are found in TM (du Plessis-Stoman et al., 2009). In addition, microorganisms like 
fungi have been known to be produce mycotoxins which are responsible for allergenic compounds (ref).  It is necessary for the 
plant material to be screened of microbial population present in raw plant to preserve the quality of TM.  
Heavy metals, such as mercury (Hg), lead (Pb), and arsenic (As), are well-known for their ability to interfere with 
human health (Weaver et al., 1998; Jarup, 2003; Ljung et al., 2006). Researchers have studies heavy metals’ ability to cause 
chronic effects on human and their potential environmental health hazard, especially in infants and young adults since their 
respective immune system are not yet fully developed (Hough et al., 2004; Ibrahim et al., 2006; Neuberger et al., 2009).  The 
screening of heavy metals should be included among the standard protocols such as lead, mercury, copper and arsenic in the 
medicinal plant or finished product due to its abundant in TM as contaminants (Sahoo and Machikanti, 2010).  
  
Phytochemical analysis- quality control of finished products  
 
The importance of TM validation with appropriate tools as to ensure the pool of information about plant material 
species will not only inform regulations bodies about safety concerning TM, but also will also assist in learning more about 
bioactive in a particular medicinal plants. The preliminary phytochemical analysis that has been noticeable to be useful tool in the 
screening of medicinal plants’ bioactive is thin layer chromatography (TLC) and has been frequently used (Adewunmi et al., 
2001; Alshawsh et al., 2007; Pedersen et al., 2009). High performance liquid chromatography (HPLC) with diode array detection 
(DAD) has been noted to be promising tool for chemical fingerprinting. The challenges with these technologies are necessary to 
know standard medicinal plant species with known standard spectrum that will assist in the understanding of unknown peaks 
(Springfield et al., 2005; du Plessis-Stoman et al., 2009).  
 
Quantitative analysis for safety and efficacy  
 
It is believed that TM is safe for human used based on the THPs knowledge and experiences working with them and 
their patients, and often toxicity being reported are associated with miss-identified medicinal plant species. The scientifically 
validation is necessary to understand safety for those undocumented medicinal plants as to safe-guide consumers with the issues 
of poisoning by unknown medicinal plants.  Various assays has been used in medicinal plant in earl screening of active 
compounds and assays included antibacterial, antifungal, anti-inflammatory, and antioxidants activity (Pillay et al., 2001; Fennel 
et al., 2004). 
Studies have shown that the screening of medicinal plants with the above-mentioned assays should be pathogenic-
specific as to understand the activities medicinal plants have in a particular disease under study (Vuuren, 2008). Langfield et al., 
(2004) reported on the easy to use and effect method for the identification of antibacterial activities which is modified bioassay 
method. The measurement outcomes listed below assist in therapeutic or toxic effects analysis of medicinal plants when looking 
at microbial inhibitory concentrations (MIC), antioxidants properties such as hydroxyl radicals, and anti-inflammatory inhibitors 
namely: - cyclooxygenase which comes in two isoforms: COX1 and COX2 (Taylor and Staden, 2001; Fennel et al., 2004; 
Steenkamp et al., 2005).          
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Toxicological and pharmacological screening 
 
The toxicological screening of medicinal plants using human cell lines (in vitro) and animal models (in vivo) will give 
us some guidance for the selection of highly active plant extract and the results will be provide us with isolation and identification 
of useful compounds (McGaw et al., 2007). The active compounds are necessary as to understand medicinal plant properties in 
combating a particular or management of patient well-being.  However, it is crucial to take note that TM is more holistic in their 
approach towards healing processes (Houghton et al., 2007). Pharmacological studies should also be conducted as to have better 
understand on medicinal plant mode of action (van Wyk, 2008). The safety validation of TM has been looked at with particular 
interest the following two areas in vitro and in vivo for the analysis of toxic effects of medicinal plant.   
It is advisable to ensure that in vitro screenings of medicinal plants are conducted with various dosages as to quantify 
dose response curve.  Various cytotoxicity assays has been used and the choice depend on the outcomes needed to be measured 
based on a disease being studied or what the medicinal plant is targeting to treat. The measurement outcomes that can be 
undertaken in bioassays can include cell proliferation, cell morphology, and plasma membrane, cell signaling, cell differentiation, 
metabolism, DNA replication and apoptosis (Popat et al., 2001; Saad et al., 2006). The advantages of bioassay are designed to 
produce accurate results of high quality within short period of time, furthermore, most test are colometric so it easy to observe 
some changes if any during the experiment.   
Animals such as mice and rats are being in vitro experimentation can be either be acute or sub chronic toxicity analysis.  
Acute toxicity is an observational study where animal are being given different dosages and monitored for their behavioral and 
physiological are timed within the period of the experiment.  Animals are being sacrificed at the end of the experiment which 
takes with maximum of 14 days and vital organs are tested for toxicity (Soulimani et al., 2001; Déciga-Campos, et al., 2007). 
Unlike sub-chronic toxicity where rats are being used for this experiment can run up to 90 days, but suitable period is 60 days as 
to avoid rats being stressed by the experimentation. The observational changes are also recorded here with blood sample being 
taken in specified period and analyzed; and at the end of the experimentation period rats are being sacrificed and vital organs are 
measured such as liver, kidney, spleen and ovaries/ testes (Lu et al., 2005; Khader et al., 2010). In addition to the test mentioned 
here above lung pathology, hematology, plasma biochemistry and cytokines production can also be measured after 
experimentation (Jung et al., 2004; Amresh et al., 2008).    
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